Browse the corpus

Chloracne is an uncommon acneform eruption caused by exposure to halogenated aromatic hydrocarbons. The condition represents a key cutaneous marker of systemic toxicity. It is most commonly associated with occupational or environmental exposure and results from activation of the aryl hydrocarbon receptor, leading to altered keratinocyte differentiation, sebaceous gland involution, and abnormal follicular keratinization. Clinically, chloracne presents with comedones, cysts, and nodules in characteristic and atypical distributions and is often persistent and resistant to standard acne therapies. Diagnosis is primarily clinical and depends on a thorough occupational and environmental history. Management centers on prompt removal from exposure and may include topical or systemic therapies, though responses are frequently incomplete. This activity reviews epidemiology, pathophysiology, clinical presentation, evaluation, and management. It also highlights the importance of interprofessional collaboration to improve early recognition, coordinate exposure mitigation, and optimize patient outcomes. Objectives: Identify the etiology of chloracne related to exposure to halogenated aromatic hydrocarbons. Assess the characteristic appearance and distribution of chloracne lesions. Determine optimal management approaches for chloracne. Collaborate with the interprofessional healthcare team to educate, treat, and monitor patients with chloracne to improve patient outcomes. Access free multiple choice questions on this topic.

Chloracne is an acneform eruption caused by exposure to halogenated aromatic compounds. Dioxin is the most notable environmental chloracnegen,[1][2] though several compounds are recognized as endocrine-disrupting chemicals (EDCs), including polychlorinated biphenyls.[3][4][5][6][7] Agent Orange, an infamous defoliant used during the Vietnam War, is known to contain trace amounts of dioxin. Characteristic lesions include cysts, nodules, pustules, and both open and closed comedones. Classically affected sites include the malar cheeks, postauricular skin, axillae, and groin.[2] Disease severity typically follows a dose-response relationship, with high-level exposure potentially resulting in multisystem involvement, including the eyes, liver, and endocrine and nervous systems. Chloracne is also referred to as MADISH.[8]

Chloracneogens are lipophilic substances that can persist in the skin and adipose tissue for prolonged periods after exposure. Routes of exposure include direct dermal contact, ingestion, and inhalation. Most cases are associated with occupational or accidental exposure; however, the poisoning of Ukrainian President Viktor Yushchenko represents a notable case of intentional dioxin exposure.[9] Chloracne results from exposure to halogenated aromatic hydrocarbons found in fungicides, herbicides, insecticides, and wood preservatives. Specific chemicals implicated in chloracne include chlornaphthalene, chlorobenzene, polychlorinated biphenyls, polychlorinated dibenzo-p-dioxins, polychlorinated dibenzofurans, pyrazole derivatives, chlorophenol contaminants, and trifluoromethyl compounds.

Chloracne is a rare skin condition that most often is reported as a hazard of occupational exposure. It can be seen among chemical production workers and those who handled, applied, or were exposed to 2,3,7,8-tetrachlorodibenzo-para-dioxin (TCDD)–contaminated pesticides.[9] Outbreaks of chloracne have occurred following accidental mass exposures, and at least one well-known individual has been deliberately poisoned. The first documented human exposure to chemicals contaminated with TCDD was reported in 1949 after an explosion at a trichlorophenol reactor in Nitro, West Virginia. Subsequently, entire communities were affected by dioxin exposure from contaminated oil in Missouri and from industrial waste in Seveso, Italy.[10] The largest reported incident occurred in Japan in 1968, involving approximately 1600 victims.[2] During the Vietnam War, Agent Orange was widely used; however, the true prevalence of chloracne among Vietnam veterans remains unknown. Currently, the use of dioxin-containing polyhalogenated compounds is highly restricted.[11]

Chloracne is an acneform condition resulting from the persistence of toxic chemicals and their metabolites within the body. These toxins accumulate in the sebaceous glands, disrupting normal function and transforming them from lipid-producing structures into characteristic cystic hamartomas.[12] These changes are mediated through activation of the aryl hydrocarbon receptor, which is expressed in keratinocytes and sebocytes, leading to accelerated epidermal terminal differentiation (keratinization) and a shift of sebocytes toward keratinocyte-like differentiation.[13][14] Specimens from the epidermis and cyst epithelium of patients with MADISH demonstrate strong expression of small proline-rich protein 2, secretory leukocyte peptidase inhibitor, epigen, nd the nuclear factor erythroid 2–related factor 2 target, NAD(P)H dehydrogenase, quinone 1.[15] Systemically, chloracnegens act as EDCs, mimicking or interfering with endogenous hormones such as estrogens, progesterone, and androgens. They also interact with multiple receptor systems, including retinoid and aryl hydrocarbon receptors, leading to receptor overactivation and disruption of normal metabolic pathways. Consequently, EDC exposure has been associated with thyroid dysfunction, reproductive abnormalities (including cryptorchidism, hypospadias, testicular cancer, and precocious puberty in females), hematologic malignancies such as leukemia, brain tumors, neurobehavioral disorders, type 2 diabetes, and obesity.[3]

The most distinguishing histopathologic feature of chloracne is the marked absence of sebaceous glands.[8] Epidermal cysts are common and may be superficial, often with an open punctum, or present as deeper dermal cysts.

The onset and progression of systemic symptoms and cutaneous findings vary according to the duration and magnitude of toxic exposure. Following high-level exposure, systemic symptoms may develop within days, whereas chloracne lesions often appear more slowly, sometimes not until weeks to months later. Acute, high-level exposure to halogenated aromatic compounds may result in systemic symptoms, including gastrointestinal distress (nausea, vomiting, diarrhea), liver dysfunction, pancreatitis, neuropathy, and joint pain. Cutaneous lesions typically develop on the cheeks and postauricular areas and may subsequently extend to the axillae and groin. In some cases, involvement of the shoulders, chest, back, and abdomen occurs, with progression to the extremities in advanced disease. The skin may initially appear excessively oily before the characteristic lesions of chloracne emerge, including open and closed comedones (blackheads and whiteheads), nodules and cysts, and pustules. Additional cutaneous and mucosal manifestations include palmar or plantar hyperhidrosis; porphyria cutanea tarda (characterized by pigmentation, increased hair growth, and blistering on exposed skin); hypertrichosis; and hyperpigmentation of the skin, hair, or nails. Ocular findings may include conjunctivitis, hyperpigmentation of the conjunctival mucosa, and enlargement of the meibomian glands.[2][16]

A targeted history and thorough physical examination are essential for establishing an accurate diagnosis of chloracne. Toxicologic screening for halogenated aromatic hydrocarbons may be performed, but evidence regarding its diagnostic reliability is inconsistent. Historically, polyhalogenated hydrocarbons were measured in blood and urine samples. In individuals exposed to TCDD, the presence of chloracne, elevations in gamma-glutamyl transferase and triglyceride levels, and alterations in follicle-stimulating hormone and luteinizing hormone have been shown to correlate with serum TCDD concentrations.[10] However, variability in individual sensitivity to dioxins and related compounds, along with their accumulation in the skin and adipose tissue, limits the utility of serum toxic equivalency values for diagnosis.[8] Biopsy specimens from affected skin may demonstrate a marked reduction in normal sebaceous gland density. They may also show the presence of cutaneous hamartomas. Immunohistochemical analysis can be performed on biopsy tissue to assess gene expression, such as cytochrome P450 1A1.[17]

Once chloracne is diagnosed, management primarily involves eliminating further exposure to the offending chemical, which often leads to partial improvement of lesions. When cutaneous findings persist despite cessation of exposure, treatments commonly used for acne vulgaris, including topical retinoids, oral antibiotics, or systemic isotretinoin, may be considered. Comedones can be manually extracted, and cysts may be surgically excised when indicated. Isolated case reports have described successful treatment with adalimumab.[18] More recently, a small cohort of Japanese patients with long-standing dioxin-related sequelae spanning 30 to 40 years was treated with the oral cinnamaldehyde-containing antioxidant Keishibukuryogan. Treatment with this herbal medicine, which inhibits aryl hydrocarbon receptor–mediated cytochrome P450 1A1 activity and activates nuclear factor erythroid 2–related factor 2, was associated with improvements in both chloracne lesions and related systemic symptoms.[19] Patients with a history of chloracneogen exposure require longitudinal follow-up, as toxic exposures may affect organ systems beyond the skin and have been associated with an increased risk of various malignancies.

The differential diagnosis for chloracne includes acne vulgaris, Favre-Racouchot syndrome (also known as solar or senile comedones and nodular elastosis with cysts and comedones), folliculitis, dilated pore of Winer, epidermal inclusion cyst, milia, folliculotropic mycosis fungoides, and nevus comedonicus.

The prognosis of chloracne is variable and closely related to the intensity and duration of exposure to causative halogenated hydrocarbons. Cutaneous lesions may persist for prolonged periods, often months to years, even after exposure has ceased, due to the long biological half-life and lipophilic properties of compounds such as dioxins that accumulate in adipose tissue. In mild cases, gradual spontaneous improvement may occur, whereas severe disease can result in permanent scarring and disfigurement.[5] Resolution of chloracne lesions is typically slow and often incomplete, with comedones and cysts demonstrating limited responsiveness to conventional acne therapies. Early recognition and prompt removal from continued exposure are critical determinants of clinical outcome. Importantly, chloracne serves as a cutaneous marker of systemic toxicity, and prognosis must therefore account for potential extracutaneous involvement. Associated systemic effects may include hepatic dysfunction, endocrine disturbances, and an increased risk of malignancy, depending on the specific toxin involved. Accordingly, long-term follow-up is recommended. Although the cutaneous manifestations themselves are not life-threatening, the chronic nature of the disease and its systemic implications can result in substantial morbidity and negatively impact quality of life.

Chloracne is associated with a variable degree of permanent scarring. Lesions involving the malar cheeks and postauricular regions tend to be more persistent than those affecting other body sites.[2] Long-term exposure to dioxin and dioxin-like compounds may result in immunotoxicity, including immunosuppression, as well as developmental effects.[20][21] Malignancies linked to chloracneogen exposure include non-Hodgkin lymphoma, soft-tissue sarcomas (such as dermatofibrosarcoma protuberans and leiomyosarcomas), and nonmelanoma skin cancer.[22][23]

Patients with occupational risk factors such as exposure to herbicides, insecticides, fungicides, wood preservatives, or potential prior exposure to Agent Orange should be counseled regarding both the cutaneous and systemic manifestations of chloracne. Evidence linking such exposures to other health outcomes, including congenital anomalies, remains conflicting.[2] However, counseling both partners about potential reproductive risks is prudent. Patients may be reassured that, in most cases, cutaneous lesions and systemic symptoms gradually improve over time once further chemical exposure is eliminated.

Other health problems associated with chloracne include abnormal liver function, fatigue and sleep disturbance, transient peripheral neuropathy, encephalopathy leading to poor concentration or depression, hyperlipidemia (particularly increased triglycerides),[2] impotence, and type 2 diabetes. Patients should undergo regular full-body skin examinations and laboratory monitoring, including a complete blood count with differential, liver function tests, hemoglobin A1c, and serum cholesterol, to monitor for cutaneous malignancies, lymphoma, liver dysfunction, type 2 diabetes, and hyperlipidemia.

Chloracne is a rare dermatologic condition that, when present, is best managed by an interprofessional team that may include poison control specialists, dermatologists, biohazard or environmental health experts, and internists. Prompt identification of the source of exposure is essential to mitigate the risk of broader public health consequences. Chloracne represents the hallmark cutaneous manifestation and is optimally managed by a dermatologist, particularly in refractory cases. Ongoing surveillance, including regular physical examinations and laboratory monitoring, should be coordinated by an internist to detect and manage potential systemic sequelae.